Effect of the Administration of Gymnema Sylvestre on Glycemic Control, Insulin Secretion and Insulin Sensitivity in Patients With Impaired Glucose Tolerance.

Prediabetes (PD) was defined as an state in which glucose levels are above normal but not enough to meet criteria for the diagnosis of type 2 diabetes (T2D). PD can be presented as impaired fasting glucose (IFG), impaired glucose tolerance (IGT) and glycated hemoglobin A1c (A1C) altered. The International Diabetes Federation (IDF) reported that in 2013 the prevalence of IGT was 6.9% which is equivalent to approximately 316 million individuals with IGT, it is expected that by 2035 this number will increase to 417 million people affected. Many hypoglycemic effects attributed to Gymnema sylvestre have been reported, including: increase of insulin secretion, regeneration of pancreatic islet cells, increased glucose utilization in various ways and inhibition of glucose uptake in the intestine.

Start Date01 Mar 2016

Sponsor / Collaborator

University of Guadalajara

NCT02370121

/ CompletedPhase 2IIT

Effect of Gymnema Sylvestre Administration on Metabolic Syndrome, Insulin Sensitivity and Insulin Secretion

Gymnema sylvestre has demonstrated promising effects in the treatment of obesity, dyslipidemia, hypertension, insulin secretion, among others. The above mentioned findings show that Gymnema sylvestre has an excellent potential for the prevention and treatment of metabolic syndrome.

Start Date01 Feb 2013

Sponsor / Collaborator

University of Guadalajara

NCT00396851

/ Unknown statusNot ApplicableIIT

Double Blind Randomized Trial to Compare Gurmar (Gymnema Sylvestre) With Metformin in Type 2 Diabetes

The study plans to compare the glucose-lowering effect of gurmar, a herbal preparation, with metformin in patients with type 2 diabetes

Start Date01 Jan 2007

Sponsor / Collaborator

Post Graduate Institute of Medical Education & Research

[+2]

100 Clinical Results associated with Gymnema sylvestre Extract

100 Translational Medicine associated with Gymnema sylvestre Extract

100 Patents (Medical) associated with Gymnema sylvestre Extract

Literatures (Medical) associated with Gymnema sylvestre Extract

14 Jul 2023·Nutrients

Diet Plus Inositols, α-Lactalbumin and Gymnema sylvestre: The Successful Combo to Restore Body Weight and Metabolic Profile in Obese and Dysmetabolic Patients.

Article

Author: Basciani, Sabrina ; Gnessi, Lucio ; Dinicola, Simona ; Nordio, Maurizio ; Unfer, Vittorio

The primary control of dysmetabolic patients is extremely challenging worldwide, with inadequate dietary habits and sporadic physical activity among the key risk factors for metabolic syndrome onset. Nowadays, there is no exclusive treatment for this condition, and considering that preventive measures usually fail, new therapeutic approaches need to be proposed and investigated. This present pilot study compared the effects of diet alone and in association with a combination of myo-inositol and d-chiro-inositol in their 40:1 ratio, α-lactalbumin, and Gymnema sylvestre on different metabolic parameters in obese dysmetabolic patients. To this purpose, 37 patients with BMI between 30 and 40 and fasting blood glucose between 100 and 125 mg/dL were divided into two groups: (i) the control group followed a hypocaloric Mediterranean diet, (ii) while the study group was also supplemented with a daily dosage of two sachets, each one containing 1950 mg myo-inositol, 50 mg d-chiro-inositol, 50 mg α-lactalbumin, and 250 mg Gymnema Sylvestre. After a 6-month treatment, all parameters improved in both groups. Nevertheless, the treated group experienced a greater improvement, especially concerning the variation from the baseline of HOMA index, triglycerides, BMI, body weight, and waist circumference. These findings support the supplementation with myo-inositol and d-chiro-inositol in the 40:1 ratio, α-lactalbumin, and Gymnema sylvestre as a therapeutical strategy to potentiate the beneficial effects induced via dietary programs in dysmetabolic patients.

04 Apr 2023·Metabolites

Gymnema Sylvestre Supplementation Restores Normoglycemia, Corrects Dyslipidemia, and Transcriptionally Modulates Pancreatic and Hepatic Gene Expression in Alloxan-Induced Hyperglycemic Rats

Article

Author: Jabeen, Farhat ; Anwar, Haseeb ; Muzaffar, Humaira ; Irfan, Shahzad ; Bashir, Muhammad ; Qamar, Iqra

Gymnema sylvestre is traditionally used as an herbal remedy for diabetes. The effect of Gymnema sylvestre supplementation on beta cell and hepatic activity was explored in an alloxan-induced hyperglycemic adult rat. Animals were made hyperglycemic via a single inj. (i.p) of Alloxan. Gymnema sylvestre was supplemented in diet @250 mg/kg and 500 mg/kg b.w. Animals were sacrificed, and blood and tissues (pancreas and liver) were collected for biochemical, expression, and histological analysis. Gymnema sylvestre significantly reduced blood glucose levels with a subsequent increase in plasma insulin levels in a dosage-dependent manner. Total oxidant status (TOS), malondialdehyde, LDL, VLDL, ALT, AST, triglyceride, total cholesterol, and total protein levels were reduced significantly. Significantly raised paraoxonase, arylesterase, albumin, and HDL levels were also observed in Gymnema sylvestre treated hyperglycemic rats. Increased mRNA expression of Ins-1, Ins-2, Gck, Pdx1, Mafa, and Pax6 was observed, while decreased expression of Cat, Sod1, Nrf2, and NF-kB was observed in the pancreas. However, increased mRNA expression of Gck, Irs1, SREBP1c, and Foxk1 and decreased expression of Irs2, ChREBP, Foxo1, and FoxA2 were observed in the liver. The current study indicates the potent effect of Gymnema sylvestre on the transcription modulation of the insulin gene in the alloxan-induced hyperglycemic rat model. Enhanced plasma insulin levels further help to improve hyperglycemia-induced dyslipidemia through transcriptional modulation of hepatocytes.

01 Mar 2023·Phytotherapy Research

The effects of Gymnema Sylvestre supplementation on lipid profile, glycemic control, blood pressure, and anthropometric indices in adults: A systematic review and meta‐analysis

Review

Author: Wong, Alexei ; Bagheri, Reza ; Davoodi, Sayed Hosein ; Asbaghi, Omid ; Rafiei, Mohammad Mahdi ; Asiabar, Mojtaba Mahdavi ; Khalili, Pardis ; Nosratabadi, Saeed ; Ashtary‐Larky, Damoon ; Zamani, Mohammad

AbstractThere is a growing interest in the considerable health benefits of Gymnema Sylvestre (GS) supplementation, as some studies have reported that it may improve cardiometabolic risk factors. However, the widespread impact of GS supplementation on the parameters mentioned above is not fully resolved. Consequently, this study aimed to examine the effects of GS supplementation on lipid profile, glycemic control, blood pressure, and anthropometric indices in adults. Eligible randomized controlled trials (RCT), published up to November 2021, were identified through PubMed, Scopus, and ISI Web of Science databases. Six studies were included and analyzed using a random‐effects model to calculate weighted mean differences (WMDs) with 95% confidence intervals (CI). All studies were conducted in adults that used a GC supplement (>1 week) and assessed our selected cardiovascular risk factors. Outcomes revealed that GS supplementation significantly decreased triglyceride (p < .001), total cholesterol (p < .001), low‐density lipoprotein (p < .001), fasting blood sugar (p < .001), and diastolic blood pressure (p = .003). Some limitations, including notable heterogeneity, low quality of studies, and lack of diversity among research participants, should be considered when interpreting our results. Our outcomes suggest that GS supplementation may improve cardiovascular risk factors. Future large‐high‐quality RCTs with longer duration and various populations are needed to firmly establish the clinical efficacy of the plant.

News (Medical) associated with Gymnema sylvestre Extract

06 Sep 2023

·www.prnewswire.com

Elevate Your Fitness Journey with MitoSculpt by Nutrishop

MitoSculpt by Illicit Labs launches exclusively at Nutrishop HENDERSON, Nev., Sept. 6, 2023 /PRNewswire/ -- Nutrishop® is proud to announce the launch of MitoSculpt™ by Illicit Labs®. This revolutionary metabolic formula was meticulously crafted with cutting-edge ingredients to support your fitness journey. MitoSculpt is stimulant-free, which makes it a great choice for those looking to manage their weight without the effects of high stimulants. This innovative product is now available exclusively at Nutrishop locations nationwide and online at NutrishopUSA.com. View our product highlight video on YouTube here. Continue Reading "MitoSculpt sets itself apart by providing a refreshing yet versatile alternative for those seeking a gentler approach." Tweet this Mitosculpt is a revolutionary, stimulant-free metabolic formula meticulously crafted with cutting-edge ingredients to support your fitness journey. It is now available online at NutrishopUSA.com and at Nutrishop locations nationwide. "We are always on a mission to introduce new products to help our customers achieve their health and fitness goals in ways that work for them," said Bryon McLendon, founder and CEO of Nutrishop. "In a market overflowing with formulas centered around stimulant-based ingredients, MitoSculpt sets itself apart by providing a refreshing yet versatile alternative for those seeking a gentler approach." At the heart of MitoSculpt are two key ingredients: MitoBurn® and InnoSlim®. These are included in the formula in their respective clinically-studied amounts. MitoBurn is a patented form of L-Beta-amino isobutyric acid (L-BAIBA), which is produced in skeletal muscle during exercise and has been shown in studies to impact carbohydrate and fat metabolism in humans. InnoSlim is a stimulant-free, patented compound that blends the plant-derived Panax Notoginseng root with the Chinese herb Astragalus Membranaceus to help support blood sugar and lipid metabolism. MitoSculpt's formula is further enriched with the following potent ingredients: Caralluma Fimbriata – derived from an edible cactus and often used for endurance purposes. Green Coffee Bean Extract – an extract of unroasted, green coffee beans found in many weight-management supplements today. Gymnema Sylvestre – a plant native to India and Africa with a history of use in Ayurvedic medicine. Fucoxanthin – a carotenoid abundant in brown seaweed. ForsLean ® – a trademarked ingredient derived from Coleus Forskohlii, a plant native to India. "For those who prefer stimulants, MitoSculpt stacks really well with stimulant-based thermogenic supplements for an even greater effect when it comes to supporting your fitness journey," said McLendon. "Nutrishop offers an array of effective and advanced stimulant-based thermogenic products, such as our widely popular Thermovex, as well." The suggested use for MitoSculpt is as follows: on training days, take 1 serving (3 veggie capsules) prior to exercise. On non-training days, take 1 serving in the morning. As always, Nutrishop recommends speaking with your health care provider before embarking on any fitness journey to ensure health and safety first. MitoSculpt is now available exclusively at Nutrishop locations across the United States and at NutrishopUSA.com. For more information, click here. About NUTRISHOP® Since 2003, NUTRISHOP® has helped countless individuals live a fit, healthy, happy lifestyle. Nutrishop stores offer customers a low-price guarantee on a wide array of cutting-edge dietary supplements, exceptional, individualized customer service, easy-to-follow meal plans, body composition assessment tools, and sound nutritional guidance. The Nutrishop business model focuses primarily on franchisee-owned and operated stores that provide consumers with the tools to achieve their health and fitness goals. For more information, visit NutrishopUSA.com and follow on Instagram @NutrishopUSA. To learn more about becoming a Nutrishop franchisee, visit NutrishopFranchise.com. SOURCE Nutrishop

Drug Approval

100 Deals associated with Gymnema sylvestre Extract

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Glucose Intolerance	Phase 2	MX	University of Guadalajara	01 Mar 2016
Metabolic Syndrome	Phase 2	-	University of Guadalajara	01 Feb 2013

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT02708966 (CTgov)	Phase 2	Glucose Intolerance	30	Gymnema Sylvestre (Gymnema Sylvestre)	(ivgtixjlwt) = kqhsbckvtf absbucxbrl (jtaczrtxrg, kpxzkehnop - wxiuzsmbfm) View more	-	18 Nov 2020
				Placebo (Placebo)	(ivgtixjlwt) = bzabzyagfi absbucxbrl (jtaczrtxrg, ydvypifliv - htcoepxllg) View more
NCT02370121 (CTgov)	Phase 2	Metabolic Syndrome	24	Placebo (Placebo)	(dzqvrxpccb) = bftghkvfyb zrdhmbflfq (cgrxvxozxs, wxebnbxyea - bvslxdqlwp) View more	-	03 Jun 2016
				Gymnema Sylvestre (Gymnema Sylvestre)	(dzqvrxpccb) = zoehftiifz zrdhmbflfq (cgrxvxozxs, yoadwyeman - jsmqrcgeew) View more

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis

Gymnema sylvestre Extract

Overview

Basic Info

Related

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Regulation